Skip to Main Content

President Trump may be expecting a tremendous drop in prescription drug prices, but more than two dozen payers think otherwise: They foresee their per-unit acquisition costs rising between 3 percent and 5 percent annually over the next three years, according to a new survey by Cowen analysts.

Moreover, 13 percent of the payers attributed a substantial portion of those anticipated increases to more higher priced, newer medicines. By contrast, 40 percent of payers last year expected cost increases would be due to new therapies with high price tags.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!